Greg Bosch brings over 30 years in healthcare to Panavance with leadership of commercial, operations, and R&D teams in the US and Europe. His general management experience in the life science industry spans the pharmaceutical, biologics and medical device segments including building a biosurgery business to $220M in 5 years, acquiring public and private companies, and taking public a company. Prior to joining Panavance Greg was CEO of Geistlich Pharma North America where he led a cross functional team to achieve the market leadership position in regenerative medicine in the US dental field. While at Geistlich, he also led the company's global oncology program and was responsible for the team developing Panavance's proprietary small molecule drug compound GP-2250 from early R&D through the clinical studies. Earlier in his career he was the President and CEO of PuriCore PLC where he led a successful IPO on the London Stock Exchange. Prior to his experience with PuriCore he held roles of increasing responsibility at Baxter International including General Manager of the BioSurgery Business, Vice President of Strategic Planning and Assistant to the President. Greg currently serves on the Board of Kibow Biotech, Inc. Greg earned his B.A. in Public Policy from Duke University and MBA from DePaul University.